Is The Surgical Treatment for Patients with Advanced Lung Cancer beneficial? Pro and Con
description
Transcript of Is The Surgical Treatment for Patients with Advanced Lung Cancer beneficial? Pro and Con
April 27, 2007, AntalyaApril 27, 2007, Antalya 11
Is The Surgical Treatment for Is The Surgical Treatment for Patients with Advanced Lung Cancer Patients with Advanced Lung Cancer
beneficial?beneficial?ProPro and Conand Con
Ufuk Yilmaz M.D. Ufuk Yilmaz M.D. Suat Seren Chest Disease and Surgery Training and research Suat Seren Chest Disease and Surgery Training and research
Hospital, Izmir Hospital, Izmir
April 27, 2007, Antalya 2
► In patients with suspected NSCLC;In patients with suspected NSCLC;
The initial evaluation includes both the The initial evaluation includes both the diagnosis of the primary tumor and the diagnosis of the primary tumor and the determination of the extent of tumor spread determination of the extent of tumor spread to regional and distant lymph nodes as well to regional and distant lymph nodes as well as to other structuresas to other structures
April 27, 2007, Antalya 3
► The accurate staging of NSCLC is central to The accurate staging of NSCLC is central to determining the appropriate stage determining the appropriate stage dependent therapeutic choices.dependent therapeutic choices.
April 27, 2007, Antalya 4
► Almost all patients with stage IV non-small Almost all patients with stage IV non-small cell lung cancer (NSCLC) have diffusely cell lung cancer (NSCLC) have diffusely metastatic disease, and therefore, the metastatic disease, and therefore, the standard of care for NSCLC is standard of care for NSCLC is chemotherapy or palliative care. chemotherapy or palliative care.
► These patients are usually considered These patients are usually considered unsuitable for surgery with curative intentunsuitable for surgery with curative intent..
April 27, 2007, Antalya 5
Big QuestionBig Question
►Does these patients be sutiable for curative Does these patients be sutiable for curative surgery?surgery?
April 27, 2007, Antalya 6
Answers, which one?Answers, which one?
►No ?No ?
► Yes ?Yes ?
April 27, 2007, Antalya 7
My answerMy answer
►No No ►These patients does not be sutiable These patients does not be sutiable
for curative surgery.for curative surgery.
April 27, 2007, Antalya 8
►Why no?Why no?
April 27, 2007, Antalya 9
Quality of the evidenceQuality of the evidence
Good = evidence based on good randomized controlled Good = evidence based on good randomized controlled trials or meta-analyses trials or meta-analyses
Fair = evidence based on other controlled trials or Fair = evidence based on other controlled trials or randomized controlled trials with minor flaws randomized controlled trials with minor flaws
Low = evidence based on nonrandomized, case-control, or Low = evidence based on nonrandomized, case-control, or other observational studies other observational studies
Expert opinion = evidence based on the consensus of the Expert opinion = evidence based on the consensus of the carefully selected panel of experts in the topic field. There carefully selected panel of experts in the topic field. There are no studies that meet the criteria for inclusion in the are no studies that meet the criteria for inclusion in the literature review. literature review.
April 27, 2007, Antalya 10
Pitfalls in the interpretation of data Pitfalls in the interpretation of data regarding to the treatment regarding to the treatment
The number of patients studiedThe number of patients studied
Retrospective trialRetrospective trial
BiasBias
Heterogeneous patient Heterogeneous patient populationspopulations
No randomizationNo randomization
April 27, 2007, Antalya 11
From an oncological point of From an oncological point of viewview
► The potential benefit from metastasectomy The potential benefit from metastasectomy and and
Detailed tumor evaluation Detailed tumor evaluation
Distant spread of the primary tumorDistant spread of the primary tumor
The resectability of the metastasesThe resectability of the metastases
The resectability of the primary The resectability of the primary tumortumor
The nodal involvement status The nodal involvement status
April 27, 2007, Antalya 12
► Isolated metastasisIsolated metastasis► Solitary metastasisSolitary metastasis► Soliter metastasisSoliter metastasis►OligometastasisOligometastasis► Single hematogenous distant metastasisSingle hematogenous distant metastasis
April 27, 2007, Antalya 13
To detect of the solitary To detect of the solitary metastasismetastasis(1)(1)
► The FN rate of the clinical evaluation in cI-II The FN rate of the clinical evaluation in cI-II NSCLC pts is <5%NSCLC pts is <5%
► The FN rate of clinical evaluation for pts that The FN rate of clinical evaluation for pts that include cIII NSLC is include cIII NSLC is ~~15-30%15-30%
April 27, 2007, Antalya 14
To detect of the solitary To detect of the solitary metastasismetastasis(2)(2)
► The FN rate of a contrast-enhanced brain CT The FN rate of a contrast-enhanced brain CT for metastases in NSCLC pts is <10%for metastases in NSCLC pts is <10%
► The FN rate of a bone scaning for The FN rate of a bone scaning for metastases in NSCLC pts is metastases in NSCLC pts is ~~ 4-6% 4-6%
► The FN rate of a contrast-enhanced liver CT The FN rate of a contrast-enhanced liver CT for metastases in NSCLC pts is <10%for metastases in NSCLC pts is <10%
April 27, 2007, Antalya 15
To detect of the solitary To detect of the solitary metastasismetastasis(3)(3)
► The FN rate of the PET scaning for The FN rate of the PET scaning for metastases in NSCLC pts is <8%metastases in NSCLC pts is <8%
April 27, 2007, Antalya 16
To detect of the solitary To detect of the solitary metastasismetastasis(4)(4)
► Monoclonal antibodies to epithelial markers Monoclonal antibodies to epithelial markers expressed in cancer cells have shown that occult expressed in cancer cells have shown that occult tumor cells are often present in distant sites, even tumor cells are often present in distant sites, even though they cannot be seen using conventional though they cannot be seen using conventional microscopy.microscopy.
► Occult metastasis has correlated with worse Occult metastasis has correlated with worse disease-free survival and a higher rate of recurrens.disease-free survival and a higher rate of recurrens.
April 27, 2007, Antalya 17
Most common sites of exthrathoracic Most common sites of exthrathoracic metastases in NSCLCmetastases in NSCLC
►Brain, bone, liver, adrenal glandsBrain, bone, liver, adrenal glands
►Lung, plevra, subcutaneous tissueLung, plevra, subcutaneous tissue
April 27, 2007, Antalya 18
Liver metastases from lung cancer:is surgical Liver metastases from lung cancer:is surgical resection justified ?resection justified ?
I. Di Carlo . Ann Thorac Surg I. Di Carlo . Ann Thorac Surg 20032003; 76: 291-3.; 76: 291-3.
► Resection of the liver for metastatic lesions Resection of the liver for metastatic lesions has largely been done for secondary has largely been done for secondary colorectal or neuroendocrine tumors, colorectal or neuroendocrine tumors,
► Should it be considered whenever there is Should it be considered whenever there is an isolated lesion.an isolated lesion.
► A successful resection of an isolated A successful resection of an isolated secondary hepatic lesion from a lung secondary hepatic lesion from a lung primary tumor, which wasprimary tumor, which was resected resected approximately 4 years beforehand approximately 4 years beforehand
April 27, 2007, Antalya 19
Isolated solitary splenic metastasis of a pulmonary tumor: a successful
surgicapproach in one stage A. Şanlı ve ark. Türk Göğüs Kalp Damar Cerrahisi DergisiA. Şanlı ve ark. Türk Göğüs Kalp Damar Cerrahisi Dergisi 2006 2006; 14: 73-5.; 14: 73-5.
► T3N0M1 Lung adenocarcinoma, 64 years-oldT3N0M1 Lung adenocarcinoma, 64 years-old
► Left posterolateral thoracotomy + Phrenotomy ,chest Left posterolateral thoracotomy + Phrenotomy ,chest wall resection , left pneumonectomy ve splenectomy .wall resection , left pneumonectomy ve splenectomy .
► Adjuvant chemotherapyAdjuvant chemotherapy
► SSurgical approach in one stageurgical approach in one stage
April 27, 2007, Antalya 20
►The prognosis of the pts with brain The prognosis of the pts with brain metastasis is poor.metastasis is poor.
►The results of surgical treatment of The results of surgical treatment of synchronous brain metastases along synchronous brain metastases along with the primary tumor is controversialwith the primary tumor is controversial
April 27, 2007, Antalya 21
Survival results of surgical resection of brain Survival results of surgical resection of brain metastases and primary tumor metastases and primary tumor
(retrospective studies)(retrospective studies)
NoNo % op % op MortalitMortalityy
MST(m)MST(m) 2y (%)2y (%) 5y (%)5y (%)
MussiMussi 1515 00 1818 -- 6.66.6
MagillianMagillian 4141 22 1313 3131 2121
RossiRossi 4040 22 -- 2525 1313
TorreTorre 2121 00 1313 3535 1010
BonnetteBonnette 103103 22 1212 2828 1111
HoseckHoseck 1212 00 6.26.2 -- --
ChidelChidel 1313 -- 2020 -- --
GranoneGranone 2020 00 2323 4747 14*14*
BillingBilling 2828 00 2424 5454 2121
April 27, 2007, Antalya 22
Prognostic factors pts with NSCLC with syncronous, Prognostic factors pts with NSCLC with syncronous, isolated brain metastases undergoing combined isolated brain metastases undergoing combined
surgical treatmentsurgical treatment
Pts noPts no HistologyHistology N N T T R0(P)R0(P)
Mussi (1996)Mussi (1996) 1212 Y(SCC)Y(SCC) __ __ __
Granone(1989-99)Granone(1989-99) 2020 Y(Adeno)Y(Adeno) YY NN __
Billing (1975-97)Billing (1975-97) 2828 __ YY __ __
Torre (1975-87)Torre (1975-87) 2121 __ YY __ __
Getman (1994-99)Getman (1994-99) 16 16 NN NN NN __
Burt (1992)Burt (1992) 3232 __ NN NN YY
Bonette (1985-98)Bonette (1985-98) 103103 Y(Adeno)Y(Adeno) NN NN NN
April 27, 2007, Antalya 23
Surgical treatment of solitary adrenal metastasis from Surgical treatment of solitary adrenal metastasis from NSCLCNSCLC
O. Mercier.O. Mercier.J Thorac Cardiovasc SurgJ Thorac Cardiovasc Surg 2005;130:136-140 2005;130:136-140
► 1989 - 2003, 23 patients ( synchronous in 6 pts , 1989 - 2003, 23 patients ( synchronous in 6 pts , metachronous in 17 pts. metachronous in 17 pts.
► The overall 5-year survival was 23.3% The overall 5-year survival was 23.3%
► All patients with a disease-free interval of less than 6 months All patients with a disease-free interval of less than 6 months died within 2 years of the operation. died within 2 years of the operation.
► Surgical resection of metachronous isolated adrenal Surgical resection of metachronous isolated adrenal metastasis with a DFI of greater than 6 months can provide metastasis with a DFI of greater than 6 months can provide long-term survival in patients previously undergoing complete long-term survival in patients previously undergoing complete resection of the primary NSCLC. resection of the primary NSCLC.
April 27, 2007, Antalya 24
Surgical treatment of solitary adrenal metastasis from Surgical treatment of solitary adrenal metastasis from NSCLC NSCLC H. PorteH. Porte Ann Thorac Surg 2001;71:981-985Ann Thorac Surg 2001;71:981-985
► 43 pts ; 32 synchronously 43 pts ; 32 synchronously ► Median survival was 11 months, and 3 patients Median survival was 11 months, and 3 patients
survived more than 5 years survived more than 5 years
► Survival was not affected by the histology of the Survival was not affected by the histology of the NSCLC, TNM stage, any adjuvant and neoadjuvant NSCLC, TNM stage, any adjuvant and neoadjuvant treatment treatment
► No clinical or pathologic criteria were detected to No clinical or pathologic criteria were detected to identify patients amenable to potential cure. identify patients amenable to potential cure.
April 27, 2007, Antalya 25
Adrenalectomy for solitary adrenal metastases Adrenalectomy for solitary adrenal metastases from NSCLC.from NSCLC. Pfannschmidt J. Lung Cancer 2005;49(2):203Pfannschmidt J. Lung Cancer 2005;49(2):203
► Between 1997 and 2000,Between 1997 and 2000,► 11 pts (11 pts (methacronous -6 pts-, Synchronous-5 pts-methacronous -6 pts-, Synchronous-5 pts-))► Pts with synchronous adrenal metastases Pts with synchronous adrenal metastases
MST; 10.3 m.MST; 10.3 m.
April 27, 2007, Antalya 26
Resected solitary adrenal metastasis from Resected solitary adrenal metastasis from non-small cell lung cancer.non-small cell lung cancer. Aranguren D. Lung Cancer Aranguren D. Lung Cancer
2005;49(2) S2:2342005;49(2) S2:234
► 1984 to 20041984 to 2004► 31 pts (14 synchronously)31 pts (14 synchronously)► R0; a median TTP of 7m, and a MST of 15 m.R0; a median TTP of 7m, and a MST of 15 m.►Non-R0; TTP of 3m, and a MST of 12 m.Non-R0; TTP of 3m, and a MST of 12 m.► 7 (37%) resected pts alive at 3 years (4 7 (37%) resected pts alive at 3 years (4
synch, 3 meta)synch, 3 meta)
April 27, 2007, Antalya 27
Pulmonary MetastasesPulmonary Metastases
► The 1997 staging system classifies a The 1997 staging system classifies a satellite nodule of cancer that is within the satellite nodule of cancer that is within the same lobe as the primary tumor as T4(stage same lobe as the primary tumor as T4(stage IIIb), and additional foci of cancer in IIIb), and additional foci of cancer in different lobes as M1 (stage IV)different lobes as M1 (stage IV)
April 27, 2007, Antalya 28
Pulmonary MetastasesPulmonary Metastases
► The classification of pulmonary metastases The classification of pulmonary metastases is difficult because of the existence of is difficult because of the existence of several factors that appear to influence several factors that appear to influence patient outcome.patient outcome.
-Pts with bronchioalveolar cancers-Pts with bronchioalveolar cancers
-Pts with same-lobe satellite nodules-Pts with same-lobe satellite nodules
April 27, 2007, Antalya 29
Survival following resection of a primary lung Survival following resection of a primary lung cancer and a pulmonary metastasis cancer and a pulmonary metastasis
Detterbeck FC.Lung Cancer. An evidence-based guide for the practicing clinicianDetterbeck FC.Lung Cancer. An evidence-based guide for the practicing clinician
NN % adeno% adeno % BAC% BAC % SLSN% SLSN % 5-year% 5-year
NarukeNaruke 146146 6868 __ 6161 88
DeslauriesDeslauries 8484 2525 55 8181 2222
NakajimaNakajima 5050 8484 5858 9494 3030
WatanabeWatanabe 4949 5656 __ __ 2222
YanoYano 4747 6262 __ 8383 3333
SuzukiSuzuki 4646 100100 MostMost 100100 3636
YoshinoYoshino 4242 7474 __ __ 2424
ShimizuShimizu 4242 6767 __ 8888 2626
FukuseFukuse 4141 6666 __ 4949 2626
April 27, 2007, Antalya 30
Survival following resection of a primary lung Survival following resection of a primary lung cancer and a pulmonary metastasis cancer and a pulmonary metastasis
Detterbeck FC.Lung Cancer. An evidence-based guide for the practicing clinicianDetterbeck FC.Lung Cancer. An evidence-based guide for the practicing clinician
► Yano et al Yano et al ;; 8 pts , 5-year survival 0%8 pts , 5-year survival 0%► Shimizu et alShimizu et al ;; 5 pts, 5-year survival 20%5 pts, 5-year survival 20%► Fukuse et al Fukuse et al ;; 21 pts, 3-year survival 21 pts, 3-year survival
21%21%► Naruke et al Naruke et al ;; 57 pts , 5-year survival 57 pts , 5-year survival
5%5%
April 27, 2007, Antalya 31
Prolonged survival after extracranial metastasectomy from Prolonged survival after extracranial metastasectomy from synchronous resectable lung cancersynchronous resectable lung cancer
V. Ambrogi Ann of Surg Oncology 2001:8;663V. Ambrogi Ann of Surg Oncology 2001:8;663
► 9 pts with NSCLC with synchronous, 9 pts with NSCLC with synchronous, solitarymetastasis: adrenal (5), cutaneous (2), solitarymetastasis: adrenal (5), cutaneous (2), axillary lymph node (1),kidney (1). axillary lymph node (1),kidney (1).
► 5-year survival rate was 55.6%. Five patients who 5-year survival rate was 55.6%. Five patients who had adrenal (3), or skin (1), or axillary (1) had adrenal (3), or skin (1), or axillary (1) metastases, survived more than 5 years. All N2 metastases, survived more than 5 years. All N2 patients (n = 2) died.patients (n = 2) died.
► Unexpected, prolonged survival was demonstrated Unexpected, prolonged survival was demonstrated in our limited series in our limited series
April 27, 2007, Antalya 32
Oligometastatic NSCLC: A Multidisciplinary Approach Oligometastatic NSCLC: A Multidisciplinary Approach in the PET Scanin the PET Scan EraEra
T. M. De Pas, Ann Thorac Surg 2007;83:231-234T. M. De Pas, Ann Thorac Surg 2007;83:231-234
► Analyzed the data from 1509 pts who Analyzed the data from 1509 pts who underwent surgical procedures for a primary underwent surgical procedures for a primary NSCLC from 2000 to 2005 , after a work-up NSCLC from 2000 to 2005 , after a work-up that included a PET scan.that included a PET scan.
► Ten pts (0.7%) exhibited a solitary Ten pts (0.7%) exhibited a solitary hematogenous metastasis.hematogenous metastasis.
April 27, 2007, Antalya 33
Oligometastatic NSCLC: A Multidisciplinary Approach Oligometastatic NSCLC: A Multidisciplinary Approach in the PET Scanin the PET Scan EraEra
T. M. De Pas, Ann Thorac Surg 2007;83:231-234T. M. De Pas, Ann Thorac Surg 2007;83:231-234
► The data from 1,509 pts who underwent surgical procedıres The data from 1,509 pts who underwent surgical procedıres for a primary NSCLC, after a workup that included a PET scanfor a primary NSCLC, after a workup that included a PET scan
► 10 pts (0.7%) . The median overall survival was 26 months, 10 pts (0.7%) . The median overall survival was 26 months, and the median time to progression was 20 months; 6 and the median time to progression was 20 months; 6 patients were alive at the time of analysis, with a median patients were alive at the time of analysis, with a median follow-up of 30 months. follow-up of 30 months.
April 27, 2007, Antalya 34
Oligometastatic NSCLC: A Multidisciplinary Approach Oligometastatic NSCLC: A Multidisciplinary Approach in the PET Scanin the PET Scan Era Era
T. M. De Pas, Ann Thorac Surg 2007;83:231-234T. M. De Pas, Ann Thorac Surg 2007;83:231-234
P stageP stage Site of Site of metmet
Treatment of Treatment of metmet
TTP(m)TTP(m) OS(m)OS(m)
11 ypT2N0ypT2N0 BrainBrain WBRWBR 1919 3030
22 pT1N2pT1N2 BrainBrain S+SRTS+SRT 1818 1818
33 ypT2N0ypT2N0 BrainBrain SRTSRT 3030 3333
44 ypT2N0ypT2N0 BoneBone RTRT 66 1010
55 ypT2N2ypT2N2 BrainBrain SRTSRT 1616 2222
66 ypT4N1ypT4N1 AdrenalAdrenal SS 1515 2222
77 ypT0N0ypT0N0 BrainBrain SRTSRT 2323 2323
88 ypT2NxypT2Nx AdrenalAdrenal TABTAB 3232 3232
99 ypT2N2ypT2N2 BrainBrain SRTSRT 55 1515
1010 pT2N2pT2N2 BoneBone S+RTS+RT 99 99
April 27, 2007, Antalya 35
►Clear data regarding this issue is Clear data regarding this issue is lackinglacking